Clinical efficacy of subcutaneous and sublingual allergen-specific immunotherapy of allergic rhinitis and conjunctivitis
- Authors: Kozulina IE1, Pavlova KS1, Kurbacheva OM1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 13, No 6 (2016)
- Pages: 63-69
- Section: Articles
- URL: https://bakhtiniada.ru/raj/article/view/120639
- DOI: https://doi.org/10.36691/RJA389
- ID: 120639
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I E Kozulina
Institute of Immunology
Email: ksenimedical@gmail.com
Moscow, Russia
K S Pavlova
Institute of ImmunologyMoscow, Russia
O M Kurbacheva
Institute of ImmunologyMoscow, Russia
References
- Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «ФАРМАРУС ПРИНТ МЕДИА». 2010, 228 с.
- Bousquet J., Lockey R., Mailing H.J. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, p. 1-42.
- Calderon M.A., Alves B., Jacobson M. et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. 2007, v. 24, CD001936.
- Jutel M., Agache I., Bonini S. et al. International Consensus On (ICON) Allergy Immunotherapy (AIT). J. Allergy Clin. Immunol. 2015, v. 136, p. 556-568.
- Normansell R., Kew K.M., Bridgman A.L. Sublingual immunotherapy for asthma. Cochrane Database Syst. Rev. 2015, v. 28, doi: 10.1002/14651858.
- Radulvic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2010, v. 8, doi: 10.1002/14651858.
- Tam H., Calderon M.A., Manikam L. et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst. Rev. 2016, v. 12, 10.1002/14651858.
- Novembre E., Galli E., Landi F. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114, p. 851-857.
- Pichler C.E., Marquardsen A., Sparholt S. et al. Specific immunotheraoy with Dermatophagoides pteronyssinus and D. farina results in decreased bronchial hyperreactivity. Allergy. 1997, v. 52, p. 274-283.
- Calderon M.A., Larenas D., Kleine-Tebbe J. et al. European academy of allergy and clinical immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy. 2011, v. 66, p. 1345-1359.
- Nelson H., Cartier S., Allen-Ramey F. et al. Network meta-analysis shows commercialized subcutaneous and sublin gual grass products have comparable efficacy. J. Allergy Clin. Immunol. Pract. 2015, v. 3, p. 256-266.
- Worm M., Rak S., De Blay F. et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: result of a double-blind, placebo-controlled study. Clinical and Translational Allergy. 2014, v. 4, p. 1-11.
- Khinchi M.S., Poulsen L.K., Carat F. et al. Clinical efficacy of sublingual and subcutaneous birch pollen AIT a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004, v. 59, p. 45-53.
- Pfaar O., Demoly P., Gerth van Wijk R. et al. EAACI. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014, v. 69, p. 854-867.
- Juniper E.F., Guyatt G.H., Griffith L.E., Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J. Allergy Clin. Immunol. 1996, v. 98, p. 843-845.
- Курбачева О.М., Павлова К.С. Оценка клинической эффективности аллерген-специфической иммунотерапии при лечении больных атопическими респираторными заболеваниями. Физиол. и патол. иммунной системы. 2005, № 5, с. 3-6.
Supplementary files
